The short answer: ChondroFiller is not available on the NHS

ChondroFiller is not available on the NHS. No GP referral opens a route to it, no NICE health technology appraisal has been initiated for the product as of mid-2026, and no NHS commissioning pilot is under way. Patients who ask their GP about ChondroFiller will find there is simply no pathway — the treatment does not exist within NHS procurement.

The reason is regulatory rather than clinical. Before an NHS hospital can stock or fund a novel medical device, the product must complete a health technology appraisal or enter a national commissioning framework. That process has not been initiated for ChondroFiller. As a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany, ChondroFiller may lawfully enter UK private practice without that review — and that is the route it has taken. There is currently no indication that a NICE appraisal is forthcoming.

For context, the only knee cartilage repair interventions the NHS does commission in England are Autologous Chondrocyte Implantation, approved by NICE in 2017, and Spherox, available via NHS England from 2018. Both are surgical, cell-based procedures targeting a different part of the clinical pathway — they are not comparable injectable scaffold treatments.

In practice, this means patients who are suitable for ChondroFiller should plan from the outset on the self-funded private route. The sections below explain what that involves, what it costs, and where to find a qualified clinician.

What the NHS does fund for cartilage — and why ChondroFiller sits outside it

Autologous Chondrocyte Implantation (ACI) and Spherox represent the outer boundary of what the NHS will pay for in cartilage repair. ACI, approved by NICE in 2017, involves harvesting chondrocytes from the patient's own joint, culturing them in a laboratory over several weeks, then reimplanting them in a second surgical procedure under general anaesthetic. Spherox, commissioned by NHS England from 2018, follows a comparable cell-culture model, again requiring theatre time and a staged surgical approach.

ChondroFiller occupies a different position on the treatment pathway altogether. It is not a cell-culture procedure and does not require an operating theatre. The current service pathway is an ultrasound-guided outpatient injection — a 30–45 minute appointment under local anaesthetic in which the injectable collagen scaffold is placed directly into the focal defect, where it gels in situ and supports the body's own repair processes through acellular matrix-induced chondrogenesis. No tissue is harvested beforehand, no laboratory stage is involved, and no surgical incision is made.

The structural difference matters for patients trying to map their options: ACI and Spherox are commissioned for a surgical, cell-based route; ChondroFiller is an injectable scaffold approach. The two categories sit at distinct points on the cartilage-repair pathway rather than competing for the same clinical slot.

Costs and what a private treatment quote covers

Guide costs for ChondroFiller in the UK are tiered by treatment volume. London Cartilage Clinic's published pricing runs from approximately £3,000 for one box through £5,500 for two boxes and £8,000 for three, rising to £9,800 for complex multi-compartment Grade III/IV defects. These figures should be treated as a starting point: patients should request a written, itemised quote at their assessment appointment, as the precise volume required depends on defect size and location, which can only be confirmed once imaging has been reviewed.

Crucially, a well-structured quote is all-inclusive. It should cover the initial consultation, real-time ultrasound guidance during the procedure, the ChondroFiller implant itself, intravenous antibiotic cover, and a six-week follow-up appointment. That breadth of inclusion matters clinically. IV antibiotic cover is standard for an implant-level intervention — ChondroFiller is a CE-marked Class III medical device, not a standard intra-articular injectable — and the structured follow-up allows the treating clinician to assess early scaffold integration and address any concerns before they develop. Both inclusions are absent from typical viscosupplementation pricing, so like-for-like comparison with simpler injection quotes is not straightforward.

ChondroFiller is imported on a per-patient prescription from Meidrix Biomedicals GmbH in Germany rather than held as standing clinic stock, which is reflected in the treatment's positioning as a tailored, individually sourced implant rather than an off-the-shelf procedure.

For patients exploring combination approaches, pairing ChondroFiller with Arthrosamid carries a separate guide cost of approximately £6,000, as the two products work through different mechanisms and serve distinct roles within the joint.

Private medical insurance: what to check before you assume you'll pay out of pocket

Most private medical insurers in the UK do not routinely cover ChondroFiller — Bupa and AXA both treat it as non-standard, meaning a standard policy will not trigger automatic reimbursement. That is the default position, and patients should start from there rather than assume either direction before checking.

The more useful question is whether a given policy might cover it on an individual basis. Bupa, Aviva, and WPA have each approved ChondroFiller in individual cases, and knowing the correct CCSD procedure codes gives any insurer conversation a concrete clinical reference point. The relevant codes are W3111 (cartilage regeneration with collagen scaffold) and W8500. Quoting these when contacting the insurer — before booking any appointment — strengthens the pre-authorisation request and signals that the treating clinician is working within a recognised coding framework.

Written pre-authorisation is essential. Verbal indications of coverage are not binding; a written confirmation protects the patient if a claim is subsequently queried. The clinic can typically advise on how to frame the submission.

Coverage terms evolve, and insurer positions change more frequently than published guides are updated. The picture described here reflects the situation as of October 2025; patients should verify current policy terms directly with their insurer before booking. A brief call at that stage takes minutes and may prevent a substantial out-of-pocket cost.

Why the practitioner matters as much as the product

Placement matters. ChondroFiller is not a generic intra-articular injection: the collagen scaffold must be deposited accurately within the defect under real-time ultrasound guidance, and how precisely that is done affects how well the material integrates. The same product, in different hands, can produce meaningfully different results.

This is why the UK's certified provider pool is small — and deliberately so. Gaining accreditation to deliver ChondroFiller involves structured training in scaffold placement technique, not simply a general familiarity with ultrasound-guided injections. That limited number of trained practitioners reflects a quality gate rather than a supply shortage.

When researching a provider, the most informative question to put to the named clinician — not to reception, and not inferred from the clinic's website — is how many ChondroFiller injections they have personally performed. Procedure volume at the clinic level tells you less than the individual consultant's hands-on experience; a practitioner who has placed the scaffold many times will have encountered and resolved the nuances that come with less frequent use.

No GP referral is required to access ChondroFiller privately. Direct self-referral is the standard route, and most clinics will arrange an initial assessment on that basis.

Booking an assessment at London Cartilage Clinic

London Cartilage Clinic at 66 Harley Street is the UK's primary certified centre for the ChondroFiller injection, led by Professor Paul Y.F. Lee — the clinician who introduced the treatment to the UK and holds ICRS Teaching Centre of Excellence accreditation. No GP letter is needed; patients book directly.

An initial assessment is the natural first step. It establishes whether the defect is focal and suitable, what treatment volume is likely to be needed, and — as a consequence — what the guide cost will be. Nothing is committed financially until that picture is clear.

For most patients researching this route, the practical path is shorter than it first appears: a self-referral to confirm suitability, a clear all-inclusive quote, a single outpatient appointment, and a recovery plan — all without navigating NHS waiting lists or surgical admission. That is the access model ChondroFiller makes possible for appropriately selected patients in the UK today.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street. Book an assessment at londoncartilage.com.